NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

Compare
333.83 +2.82 (+0.85%)
At close: August 30 at 4:00 PM EDT
330.18 -3.65 (-1.09%)
After hours: August 30 at 7:57 PM EDT
Loading Chart for AMGN
DELL
  • Previous Close 331.01
  • Open 331.95
  • Bid 314.65 x 100
  • Ask 333.95 x 100
  • Day's Range 330.30 - 335.66
  • 52 Week Range 248.38 - 346.85
  • Volume 2,173,548
  • Avg. Volume 2,076,196
  • Market Cap (intraday) 179.377B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) 57.46
  • EPS (TTM) 5.81
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield 9.00 (2.70%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 328.50

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh?et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

www.amgen.com

26,700

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMGN

View More

Performance Overview: AMGN

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AMGN
18.46%
S&P 500
18.42%

1-Year Return

AMGN
32.44%
S&P 500
25.59%

3-Year Return

AMGN
64.84%
S&P 500
25.26%

5-Year Return

AMGN
87.64%
S&P 500
93.14%

Compare To: AMGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMGN

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    179.27B

  • Enterprise Value

    232.61B

  • Trailing P/E

    57.52

  • Forward P/E

    17.21

  • PEG Ratio (5yr expected)

    2.44

  • Price/Sales (ttm)

    5.82

  • Price/Book (mrq)

    30.26

  • Enterprise Value/Revenue

    7.52

  • Enterprise Value/EBITDA

    19.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.12%

  • Return on Assets (ttm)

    4.48%

  • Return on Equity (ttm)

    49.27%

  • Revenue (ttm)

    30.93B

  • Net Income Avi to Common (ttm)

    3.13B

  • Diluted EPS (ttm)

    5.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.3B

  • Total Debt/Equity (mrq)

    1,057.30%

  • Levered Free Cash Flow (ttm)

    3.01B

Research Analysis: AMGN

View More

Company Insights: AMGN

Research Reports: AMGN

View More

People Also Watch